$2.37 $0.18 (8.2%)

04:00 PM EDT on 08/16/19

Inovio Biomedical Corp (NASDAQ:INO)

CAPS Rating: 1 out of 5

A biomedical company which deals in developing human applications of electroporation, which uses brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceuticals.

Current Price $2.37 Mkt Cap $249.0M
Open $2.22 P/E Ratio 0.00
Prev. Close $2.19 Div. (Yield) $0.00 (0.0%)
Daily Range $2.21 - $2.40 Volume 506,400
52-Wk Range $2.15 - $5.11 Avg. Daily Vol. 22

Caps

How do you think NASDAQ:INO will perform against the market?

Add Stock to CAPS Watchlist

All Players

196 Outperform
26 Underperform
 

All-Star Players

16 Outperform
13 Underperform
 

Wall Street

4 Outperform
1 Underperform
 

Top NASDAQ:INO Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

adi101 (85.66)
Submitted April 12, 2015

Find what are the attributes the Immune system latches on in an antigen (any Antigen – be it virus, bacteria, mushroom or a cancer cell), encode antigen production instructions in a RNA plasmid. Introduce into the body and let the cells themselves… More

zzlangerhans (99.83)
Submitted April 05, 2016

I can't really claim that Inovio is a bogus biotech. After all, they've gotten VGX-3100 to the threshold of phase III and achieved reasonably significant deals with Roche and MedImmune. Nevertheless, I think 670M is a generous valuation in a shaky… More

NASDAQ:INO VS S&P 500 (SPY)

Fools bullish on NASDAQ:INO are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about INO.

Recs

1
Member Avatar zzlangerhans (99.83) Submitted: 4/5/2016 2:20:05 PM : Underperform Start Price: $9.88 NASDAQ:INO Score: +115.79

I can't really claim that Inovio is a bogus biotech. After all, they've gotten VGX-3100 to the threshold of phase III and achieved reasonably significant deals with Roche and MedImmune. Nevertheless, I think 670M is a generous valuation in a shaky market for biotech given the company's long history of operations without any approved products and constantly-changing focus. Most of their current pipeline is in early stage trials and it will be a long time before the VGX-3100 phase III trial generates a significant catalyst. Cash of 183M is respectable but he quarterly burn is in the teens. This might not be an intuitive short but could be used as a counterweight for beloved long positions that are showing stretchmarks amid this spring sector rebound.

Recs

1
Member Avatar adi101 (85.66) Submitted: 4/12/2015 6:13:50 AM : Outperform Start Price: $9.20 NASDAQ:INO Score: -123.89

Find what are the attributes the Immune system latches on in an antigen (any Antigen – be it virus, bacteria, mushroom or a cancer cell), encode antigen production instructions in a RNA plasmid. Introduce into the body and let the cells themselves manufacture the part of the antigen. Let the Immune system discover the antigen and mount an immune reaction and you have immuned the body to this said antigen.
Now, use that platform to make the body produce monoclonal antibodies it needs as medicine, and heal itself.
Now use the platform to make the body make hormones it needs for as long as you design it.
Add management that is heavily invested and know how to bring non dilutive financing and behold – magic!

Recs

1
Member Avatar allstar31 (99.90) Submitted: 9/12/2014 10:58:34 PM : Underperform Start Price: $10.40 NASDAQ:INO Score: +123.02

Uses known stock promoter Redchip.com, for a pump and dump scheme. Garbage.

Leaderboard

Find the members with the highest scoring picks in INO.

Score Leader

InsiderAlerts

InsiderAlerts (< 20) Score: +386.96

The Score Leader is the player with the highest score across all their picks in INO.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
BicaChica 79.47 8/3/2009 Underperform 5Y $9.44 -74.89% +190.49% +265.38 0 Comment
epc53 27.90 7/31/2009 Underperform 5Y $8.48 -72.05% +192.53% +264.58 0 Comment
rhinomaj 92.42 8/4/2009 Underperform 3M $8.36 -71.65% +189.06% +260.72 0 Comment
uconn777 < 20 7/1/2010 Underperform 5Y $4.08 -41.91% +183.64% +225.56 0 Comment
guru111melbourne 78.99 11/24/2009 Underperform 5Y $6.20 -61.77% +160.14% +221.91 0 Comment
bdg10 < 20 1/12/2011 Underperform 5Y $5.84 -59.42% +124.97% +184.39 0 Comment
KidJones 34.61 9/3/2013 Underperform 5Y $7.16 -66.90% +74.76% +141.66 0 Comment
rqtect < 20 2/2/2012 Underperform 3W $3.00 -21.00% +117.55% +138.55 0 Comment
rlm02002 < 20 11/4/2013 Underperform 5Y $7.60 -68.82% +63.42% +132.24 0 Comment
soonerbear98 < 20 5/15/2014 Underperform 5Y $8.48 -72.05% +53.04% +125.10 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 86.43 1/24/2017 Underperform 3W $6.19 -61.71% +26.87% +88.58 0 Comment
TrackJimCramer 86.43 7/24/2014 Outperform 3W $12.98 -52.31% +14.57% -66.88 1/24/2017 @ $6.19 0 Comment
TrackStifel 91.45 5/7/2014 Outperform NS $9.36 -74.68% +54.06% -128.74 0 Comment
TrackPiperJaff 84.76 1/18/2013 Outperform NS $2.90 -18.22% +95.14% -113.36 0 Comment
TrackBreanMurray < 20 8/3/2010 Outperform NS $4.20 -43.57% +156.71% -200.28 0 Comment
TrackTWeisel 89.92 4/25/2007 Outperform NS $15.60 -84.81% +105.25% -190.06 0 Comment
TrackBWS 96.31 2/27/2007 Outperform NS $13.00 -88.31% -41.36% -46.94 4/23/2009 @ $1.52 0 Comment